PGNX News 3.50 Progenics Pharmaceuticals Inc (PGNX)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Progenics Pharmaceuticals Inc (PGNX) 3.50 $PGNX

Global Neuroblastoma Clinical Trials Review 2014 - Analysis of 9 Companies
M2 - Wed Apr 16, 10:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hfcrvd/neuroblastoma) has announced the addition of the "Neuroblastoma Global Clinical Trials Review, H1, 2014" report to their offering. Neuroblastoma Global Clinical Trials Review, H1, 2014" provides data on the Neuroblastoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuroblastoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neuroblastoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Neuroblastoma Therapeutics Clinical Trials - Progenics Pharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - APEIRON Biologics AG - United Therapeutics Corporation - Cancer Prevention Pharmaceuticals, Inc. - MabVax Therapeutics, Inc. - Eli Lilly and Company - Celgene Corporation - Biotec Pharmacon ASA For more information visit http://www.researchandmarkets.com/research/hf...roblastoma

Global Neuroendocrine Cancer Clinical Trials Review, H1, 2014
M2 - Wed Apr 09, 3:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mssxcd/neuroendocrine) has announced the addition of the "Neuroendocrine Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Neuroendocrine Cancer Global Clinical Trials Review, H1, 2014" provides data on the Neuroendocrine Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuroendocrine Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neuroendocrine Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Institutions - Novartis AG - Pfizer Inc. - Ipsen S.A. - F. Hoffmann-La Roche Ltd. - Progenics Pharmaceuticals, Inc. - Tekmira Pharmaceuticals Corp. - Threshold Pharmaceuticals, Inc. - Merck & Co., Inc. - Eli Lilly and Company - Daiichi Sankyo Company, Limited - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center - Memorial Sloan Kettering Cancer Center - Stanford University - Grupo Espanol de Tumores Neuroendocrinos - University of Wisconsin Madison - The University of Iowa - University of California, San Francisco - Alberta Health Services Visit http://www.researchandmarkets.com/research/ms...oendocrine

Progenics Pharmaceuticals CEO, Mark R. Baker, to Present at 13th Annual Needham Healthcare Conference
GlobeNewswire - Mon Apr 07, 11:00AM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq GNX), an oncology company focused on the development of innovative approaches to targeting and treating cancer, announced today that Mark R. Baker, CEO, will present at the 13th Annual Needham Healthcare Conference to be held April 8 and 9 at the Westin Grand Central Hotel in New York City. The presentation will take place on Tuesday, April 8 at 10:00 AM EST.

Progenics Pharmaceuticals and Centre for Probe Development and Commercialization Announce Agreement to Manufacture Targeted Radiotherapeutic Candidate for Ultra-Orphan Indications
GlobeNewswire - Tue Apr 01, 11:36AM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq GNX), and Centre for Probe Development and Commercialization (CPDC) today announced that Azedra, a novel targeted radiotherapy candidate resuming phase 2 registrational testing in patients suffering from pheochromocytoma and paraganglioma, will be manufactured by CPDC for the developer of the compound, Progenics Pharmaceuticals.

Lawsuits, Clinical Studies, Financial Results, and Stock Movements - Analyst Notes on Idenix, BG Medicine, Progenics, Omeros, and Opexa
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), BG Medicine, Inc. (NASDAQ: BGMD), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Omeros Corporation (NASDAQ: OMER), and Opexa Therapeutics, Inc. (NASDAQ: OPXA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register http://www.analystsreview.com/register

Progenics Pharmaceuticals (PGNX): An Off-the-Radar Potential Winner - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 7:42AM CDT
Progenics Pharma looks well positioned for a solid gain, but has been overlooked by investors lately

Top Gainers Ahead of Market -- Research on Genco Shipping & Trading, Progenics Pharma, Rambus, and Exact Sciences
PR Newswire - Wed Mar 19, 7:05AM CDT
The US markets saw a positive sentiment on Tuesday, March 18, 2014, as the NASDAQ Composite closed at 4,333.31, up 1.25%, the Dow Jones Industrial Average ended the session at 16,336.19, up 0.55% and the S&P 500 edged 0.72% higher to finish the trading session at 1,872.25. During the session, gains in the Information Technology, Health Care, and Energy sectors positively impacted the broader market. A number of stocks saw large movements, including Genco Shipping & Trading Ltd (NYSE: GNK), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Rambus Inc. (NASDAQ: RMBS), and Exact Sciences Corp. (NASDAQ: EXAS). Free technical research on GNK, PGNX, RMBS, and EXAS can be downloaded upon signing up at:

Traders Get Bullish on Shares of Progenics Pharmaceuticals, Shares Up 8.3% (PGNX)
Comtex SmarTrend(R) - Tue Mar 18, 12:46PM CDT
Progenics Pharmaceuticals (NASDAQ GNX) is one of today's best performing low-priced stocks, up 8.3% to $4.69 on 1.0x average daily volume. Thus far today, Progenics Pharmaceuticals has traded 1.6 million shares, vs. average volume of 1.5 million shares per day. The stock has outperformed the Dow (8.3% to the Dow's 0.6%) and outperformed the S&P 500 (8.3% to the S&P's 0.7%) during today's trading.

Progenics Q4 Loss Narrower Than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 10:40AM CDT
Progenics posted narrower-than-expected loss in the fourth quarter of 2013

Progenics Pharmaceuticals Announces Fourth Quarter and Year-End 2013 Financial Results and Initiates Clinical Development of Small Molecule Targeted Therapeutic
GlobeNewswire - Thu Mar 13, 8:01AM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq GNX) today announced its results of operations for the fourth quarter and year-end 2013. The company also announced that it is initiating clinical development of MIP-1095, a PSMA-targeted small molecule radiopharmaceutical for the treatment of prostate cancer.

Stock to Watch: Progenics Pharmaceuticals Up 5.9% (PGNX)
Comtex SmarTrend(R) - Tue Mar 11, 10:41AM CDT
Progenics Pharmaceuticals (NASDAQ GNX) is one of today's best performing low-priced stocks, up 5.9% to $4.88 on 1.4x average daily volume. Progenics Pharmaceuticals has traded 2.3 million shares thus far today, vs. average volume of 1.6 million shares per day. The stock has outperformed the Dow (5.9% to the Dow's 0.1%) and outperformed the S&P 500 (5.9% to the S&P's 0.1%) during today's trading.

Progenics Pharmaceuticals Sets 4Q and Year-End 2013 Financial Results Call for March 13
GlobeNewswire - Mon Mar 10, 12:48PM CDT
Progenics Pharmaceuticals, Inc., (Nasdaq GNX), an oncology company focused on developing innovative ways to target and treat prostate cancer, announced today that it will host a conference call and webcast to review fourth quarter and full-year 2013 financial results on Thursday, March 13, at 8:30 a.m. ET.

Progenics Pharmaceuticals Sets 1Q 2014 Financial Results Call for March 13
GlobeNewswire - Tue Mar 04, 11:00AM CST
Progenics Pharmaceuticals, Inc., (Nasdaq GNX), an oncology company focused on developing innovative ways to target and treat prostate cancer, announced today that it will host a conference call and webcast to review first quarter financial results on Thursday, March 13, at 8:30 a.m. ET.

Progenics to Raise Funds - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 11:10AM CST
Progenics to raise funds for research and development (R&D) activities and general corporate purposes

Progenics Pharmaceuticals prices public offering at USD4.60 per share
M2 - Mon Feb 24, 6:12AM CST
US-based medical company Progenics Pharmaceuticals (NasdaqGS GNX) said on Friday that it has priced its public offering of 7,608,696 primary shares of its common stock at USD4.60 per share.

Progenics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Fri Feb 21, 8:00AM CST
Progenics Pharmaceuticals, Inc. (Nasdaq GNX) announced today the pricing of an underwritten public offering of 7,608,696 primary shares of its common stock at a public offering price of $4.60 per share. The gross proceeds from the sale of the shares, before underwriting discounts and commissions and other offering expenses, are expected to be approximately $35 million. The offering is expected to close on or about February 26, 2014, subject to customary closing conditions. Progenics also granted the underwriters a 30-day option to purchase 1,141,304 additional shares of common stock. All of the shares to be sold in the offering are to be sold by Progenics. Progenics intends to use the net proceeds from the offering for research and development and general corporate purposes.

Progenics Pharmaceuticals to launch public offering of common shares
M2 - Fri Feb 21, 4:31AM CST
US-based oncology medicine specialists Progenics Pharmaceuticals (NasdaqGS GNX) said on Thursday that it plans to sell shares of its common stock in an underwritten public offering.

Progenics Pharmaceuticals Announces Proposed Public Offering of Common Stock
GlobeNewswire - Thu Feb 20, 3:01PM CST
Progenics Pharmaceuticals, Inc. (Nasdaq GNX) announced today that it is offering to sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Jefferies LLC is acting as sole book-running manager for the proposed offering. Progenics also intends to grant the underwriter a 30-day option to purchase additional shares of common stock on the same terms and conditions. All of the shares to be sold in the offering are to be sold by Progenics. Progenics intends to use the net proceeds from the offering for research and development and general corporate purposes.

Salix's sNDA on Relistor Gets Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 07, 4:40PM CST
Salix Pharmaceuticals announced disappointing news when the U.S. Food and Drug Administration (FDA) postponed the previously scheduled meeting on Mar 10-11 to consider the Supplemental New Drug Application (sNDA) for Relistor.

Progenics Pharmaceuticals CEO, Mark R. Baker, to Present at 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Thu Feb 06, 1:30PM CST
Progenics Pharmaceuticals, Inc. (PGNX), an oncology company focused on the development of innovative approaches to targeting and treating cancer, announced today that Mark R. Baker, CEO of Progenics, will present at the 16 Annual BIO CEO & Investor Conference which will be held February 10 and 11 at the Waldorf Astoria Hotel in New York City. The presentation will take place on Monday, February 10 at 3:00 PM EST.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

RBC Signals Gets $10 Million to Push Space Infrastructure

Updated Category News Views 44

Ground stations are the unglamorous plumbing of the space economy, and somebody finally put fresh capital behind the wrench. RBC Signals says it has received a $10 million strategic growth investment led by Washington Harbour Partners, aimed at enlarging its government-services operation and pushing several newer space-connectivity tools toward commercial use. This is a...

Continue Reading
YPF’s 2027 Reserves Platform Move Deserves Attention

Updated Category News Views 75

Reservoir software rarely makes anyone pound the table, but this one deserves a hard look. YPF, Argentina’s largest oil and gas company, says it will begin deploying Ikon Science’s MOSAIC reserves planning and management platform in 2027. That is not a new well, a pipeline expansion, or a barrel-count upgrade. It is the machinery behind the machinery: the systems used...

Continue Reading
LiberNovo's European Black Friday Sale Tests Demand

Updated Category News Views 139

A €1,339 chair has no business pretending it is an impulse buy, which is exactly why LiberNovo’s Black Friday push deserves a closer look. The Hong Kong-based ergonomic-chair seller has rolled out its Black Friday sale across the European Union and United Kingdom, with the campaign ending November 30 at 23:59 CET in the EU and 23:59 GMT in the UK. This is a...

Continue Reading
Retainers Are the Unflashy Finish to Orthodontic Care

Updated Category News Views 60

A straight smile has an inconvenient habit of remembering where it came from. That is the plainspoken point in Dr. Michael McClain’s discussion of retainers after braces or Invisalign: the dramatic part of orthodontic treatment may be over when appliances come off, but the maintenance phase has barely started. It is not glamorous, and plenty of people probably wish it...

Continue Reading
Satellite NTN's $3.22B Promise Needs Real Receipts

Updated Category News Views 56

Dead zones over oceans, deserts, and flight paths are finally becoming a serious commercial problem, not merely a neat engineering demo. That is the muscle behind the satellite non-terrestrial network, or NTN, pitch: connect aircraft, vessels, remote assets, and scattered sensors where terrestrial networks simply do not reach. MarketsandMarkets projects this market will...

Continue Reading
Yunnan Tin’s AI Materials Push Has Real Operating Teeth

Updated Category News Views 66

Tin rarely gets the spotlight until the machinery behind modern computing starts demanding more of it. Yunnan Tin Group is making the sensible case that this unglamorous metal can matter a great deal in semiconductors, artificial intelligence infrastructure and new-energy hardware. There is plenty of corporate ambition wrapped around that case, naturally, but a few...

Continue Reading
Dar Global’s $700M Qatar Bet Leans on Trump Branding

Updated Category News Views 17

Luxury property launches rarely arrive quietly, and this one came wrapped in Palm Beach ceremony, championship golf and a very loud brand name. Dar Global has formally introduced Trump International Simaisma, Qatar, a QAR 2.5 billion development—about $700 million—alongside The Trump Organization. That is a meaningful chunk of real estate ambition, not a little side...

Continue Reading
RAN Rebound Gains Speed, but 2027 Still Looks Flat

Updated Category News Views 62

Radio gear finally caught a pulse in the third quarter, and that matters after more than two years of contraction. Dell’Oro Group says worldwide Radio Access Network revenue rose at a mid-single-digit year-over-year rate in 3Q 2026, the market’s strongest quarterly growth in nearly five years. That is better than expected, which is a welcome change in a telecom...

Continue Reading
ACOLT Bets on Gold, Craft, and a Sci-Fi Story World

Updated Category News Views 22

A gold pendant moonlighting as a plot device is not the usual luxury pitch, and thank goodness for that. ACOLT, the Denver-based men's fine jewelry house founded by Colton Hindle, plans an international December 2026 launch of its Gold Collection alongside CHRYSON Volume 1: The Arrival, an original science-fiction comic. The actual hand-forged pieces are meant to show up...

Continue Reading
AIM Academy Accreditation Signals a Broader Quality Push

Updated Category News Views 0

Early-childhood education does not hand out many clean, easily comparable scorecards, which is precisely why AIM Academy’s new Cognia recognition deserves a closer look. The Alabama provider has earned Cognia Initial Accreditation, while its Pike Road center received Accreditation with Merit after its Initial Accreditation Review. That is not a revenue event, not a...

Continue Reading

Top 5 Most Recently Viewed Articles

BMO Continues to Support United Natural Foods with Price Target

Updated Category News Views 79

BMO Capital Markets Maintains Support for United Natural Foods BMO Capital Markets has reaffirmed its position regarding United Natural Foods (NYSE: UNFI), assigning a Market Perform rating with a price target set at $23.00. This decision came after productive discussions held with UNFI's senior executives, including CEO Sandy Douglas and CFO Matteo Tarditi, focusing on...

Continue Reading
HONOR's Ambitious Shift to AI Device Ecosystem Strategy

Updated Category News Views 202

HONOR's Bold New Strategy for AI Device Ecosystem In an ambitious move, global technology brand HONOR has laid out a comprehensive strategy to transform from a traditional smartphone manufacturer into a leader in the AI device ecosystem. This announcement marks a significant pivot towards embracing advanced technologies designed to maximize human potential. The new...

Continue Reading
Roche's Strategic Move: Acquiring 89bio for Innovative Therapies

Updated Category News Views 254

Roche's Strategic Acquisition of 89bio Roche's recent decision to acquire 89bio, a clinical-stage biopharmaceutical company, highlights its commitment to enhancing treatment options for patients suffering from metabolic diseases. This acquisition centers around 89bio’s innovative therapy, pegozafermin, which is showing promise for treating moderate to severe Metabolic...

Continue Reading
Baby Safety Alliance Elevates Parent Confidence in Products

Updated Category News Views 137

Baby Safety Alliance Strengthens Trust for Parents The Baby Safety Alliance is excited to announce a significant expansion of its Verification Program. This vital initiative, previously recognized as the JPMA Certification Program, aims to simplify the process for parents seeking safe and reliable products for their babies and children. Growth of the Verification Program...

Continue Reading
Ken Kendrick: A Journey of Resilience and Recognition

Updated Category News Views 646

Ken Kendrick’s Recognition by the Horatio Alger Association Ken Kendrick, the managing general partner of the Arizona Diamondbacks, has recently been honored by the Horatio Alger Association, which has selected him for its Member Class of 2025. This prestigious recognition is awarded to individuals who have overcome personal and professional adversities, showcasing...

Continue Reading